January 4, 2013 | Shield Therapeutics has selected OpenClinica Enterprise software for its clinical data management needs related to the company’s clinical trials. Shield Therapeutics develops treatments for unmet medical needs, and is currently running a Phase III program for ST10, a novel orally-delivered ferric iron-based therapy to treat iron deficiency.

“The OpenClinica system should enable us to collect data from participating clinical trial sites faster and with a higher level of quality,” said Carl Sterritt, Shield’s CEO, in a press release. “We also hope that an added benefit of the OpenClinica Enterprise Edition will be facilitation of our regulatory compliance efforts.” Press release.